Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 11/20 | 1.00 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.65 |
| ▸ | SOAT2 | O75908 | 1/20 | 0.50 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.50 |
| ▸ | PTPN12 | Q05209 | 1/20 | 0.50 |
| ▸ | PTPN22 | Q9Y2R2 | 1/20 | 0.50 |
| ▸ | TYR | P14679 | 1/20 | 0.42 |
| ▸ | ACHE | P22303 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL32889277 | 0.80 | PTPN1 (0.79) | PTPN1HSD17B1TYRACHE | |
| SCHEMBL22948232 | 0.79 | HSD17B1 (1.00) | PTPN1HSD17B1 | |
| SCHEMBL30260469 | 0.79 | HSD17B1 (1.00) | PTPN1HSD17B1 | |
| SCHEMBL23483682 | 0.79 | HSD17B1 (1.00) | PTPN1HSD17B1 | |
| SCHEMBL29384928 | 0.76 | HSD17B1 (0.62) | PTPN1HSD17B1 | |
| SCHEMBL31237827 | 0.76 | PTPN1 (0.73) | PTPN1HSD17B1TYRACHE | |
| SCHEMBL29619822 | 0.73 | PTPN1 (0.67) | PTPN1HSD17B1TYR | |
| Isoneorautenol SCHEMBL29887543 | 0.70 | PTPN1 (0.92) | PTPN1TYR | |
| Neorautenol SCHEMBL31060647 | 0.68 | PTPN1 (1.00) | PTPN1TYR | |
| SCHEMBL20960789 | 0.66 | HSD17B1 (0.61) | PTPN1HSD17B1TYRACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12102653-B2 | Ligand regulated protein-protein interaction system | ST. ANNA KINDERKREBSFORSCHUNG (AT) | 2024-10-01 | — | — | US | disclosed |
| CN-118173162-A | Method for analyzing jujube kernel compound action mechanism for regulating and treating insomnia based on network pharmacology and molecular docking and application | 武汉轻工大学 | 2024-06-11 | — | — | CN | disclosed |
| US-20240000841-A1 | LIGAND REGULATED PROTEIN-PROTEIN INTERACTION SYSTEM | ST ANNA KINDERKREBSFORSCHUNG (AT) | 2024-01-04 | — | — | US | disclosed |
| US-11844813-B2 | Ligand regulated protein-protein interaction system | ST. ANNA KINDERKREBSFORSCHUNG (AT) | 2023-12-19 | — | — | US | disclosed |
| US-20220041687-A1 | A GROUP OF CHIMERIC ANTIGEN RECEPTORS (CARS) | ST. ANNA KINDERKREBSFORSCHUNG (AT) | 2022-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220041687-A1 | A GROUP OF CHIMERIC ANTIGEN RECEPTORS (CARS) | CARS1, CD74, HAVCR2 | PTPN1 1563/4885HSD17B1 4356/4885SOAT2 3137/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.